BofA Upgrades Acadia Pharmaceuticals to Buy After 25% Pullback
BofA upgrades Acadia Pharmaceuticals (ACAD) to Buy from Neutral with a $29 price target.
/ 4 items
#ACAD↓
Mizuho Turns Bullish on Acadia: Upgrades ACAD to Outperform, Lifts Target to $35 on Remlifanserin Promise
Mizuho upgrades ACAD stock to Outperform with a $35 price target, highlighting undervalued potential in remlifanserin for Alzheimer’s psychosis, despite past setbacks with pimavanserin.
Acadia Pharmaceuticals Faces EU Setback for Rett Syndrome Drug Trofinetide
Acadia Pharmaceuticals (ACAD) receives negative CHMP vote for trofinetide EU approval despite 1,000+ patients using treatment globally. Company plans re-examination request.
Acadia Pharmaceuticals Shares Fall as ACP-101 Trial Misses Primary Endpoint
Acadia's experimental drug, ACP-101 (intranasal carbetocin), designed to treat extreme hunger (hyperphagia) in Prader-Willi syndrome patients, did not meet its main goal in the recent Phase 3 trial.